{"filing":{"accession_number":"0001193125-26-308382","cik":"0001754068","ticker":"KLRS","company_name":"Kalaris Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-20","report_date":null,"primary_document":"d125092d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526308382/d125092d8k.htm"},"events":[{"id":18695,"run_id":16812,"accession_number":"0001193125-26-308382","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Liisa Bayko as Chief Financial Officer and Treasurer effective July 20, 2026, along with detailed employment terms including $475,000 base salary, up to 40% annual bonus, and a 220,000-share stock option grant. While the section also mentions Brett Hagen's resignation as Chief Accounting Officer and Amy Vandekop's interim appointment, the primary and most substantive disclosure centers on Bayko's appointment as CFO with comprehensive compensation arrangements. This is a material executive appointment affecting the company's financial leadership.","company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","filing_date":"2026-07-20","form":"8-K","submitted_at":null,"items":[{"id":17580,"accession_number":"0001193125-26-308382","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Liisa Bayko as Chief Financial Officer and Treasurer effective July 20, 2026, along with detailed employment terms including $475,000 base salary, up to 40% annual bonus, and a 220,000-share stock option grant. While the section also mentions Brett Hagen's resignation as Chief Accounting Officer and Amy Vandekop's interim appointment, the primary and most substantive disclosure centers on Bayko's appointment as CFO with comprehensive compensation arrangements. This is a material executive appointment affecting the company's financial leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T13:16:28.484465+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17580,"accession_number":"0001193125-26-308382","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Liisa Bayko as Chief Financial Officer and Treasurer effective July 20, 2026, along with detailed employment terms including $475,000 base salary, up to 40% annual bonus, and a 220,000-share stock option grant. While the section also mentions Brett Hagen's resignation as Chief Accounting Officer and Amy Vandekop's interim appointment, the primary and most substantive disclosure centers on Bayko's appointment as CFO with comprehensive compensation arrangements. This is a material executive appointment affecting the company's financial leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T13:16:28.484465+00:00","company_name":"Kalaris Therapeutics, Inc.","ticker":"KLRS","filing_date":"2026-07-20"}]}